Clinical Trials Browser

Interventional × Dasatinib × Breast × Clear all

NCT05198843 2025-10-03

Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body

Phase 1/2 Terminated

1 enrolled 5 charts

Anatomic Stage IV Breast Cancer AJCC v8

NCT01471106 2024-07-10

Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer

Phase 2 Completed

26 enrolled 10 charts

Breast Neoplasms

NCT06355037 2024-07-08

Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT01306942 2023-03-30

Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients

Phase 1/2 Completed

37 enrolled 30 charts

Breast Neoplasms

NCT02720185 2022-06-03

Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR

Phase 2 Terminated

5 enrolled 12 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00566618 2022-02-25

Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis

Phase 1/2 Completed

31 enrolled 8 charts

Breast Neoplasms

NCT00780676 2020-09-03

Personalized Treatment Selection for Metastatic Breast Cancer

Phase 2 Terminated

97 enrolled 7 charts

Breast Neoplasms

NCT00820170 2019-08-13

Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194

Phase 1/2 Completed

55 enrolled 19 charts

Breast Neoplasms, Neoplasms

NCT00410813 2017-07-02

S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone

Phase 2 Completed

85 enrolled 18 charts

Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

NCT00754325 2016-05-26

Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor

Phase 2 Completed

100 enrolled 13 charts

Advanced Breast Cancer

NCT01410708 2016-02-17

TORI 104 Pre-Surgical Dasatinib

Phase 2 Withdrawn

Breast Neoplasms

NCT00452673 2015-03-24

Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer

Phase 1 Completed

52 enrolled 16 charts

Advanced Breast Cancer

NCT00903006 2015-02-02

Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer

Phase 1/2 Terminated

11 enrolled 6 charts

Breast Neoplasms

NCT00924352 2014-10-13

Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer

Phase 1/2 Completed

56 enrolled 14 charts

Breast Neoplasms

NCT00546104 2013-07-17

Phase II Dasatinib Study in Advanced Breast Cancer

Phase 2 Completed

31 enrolled 10 charts

Breast Neoplasms

NCT00767520 2013-02-28

Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer

Phase 2 Completed

155 enrolled 19 charts

Breast Neoplasms

NCT00817531 2012-08-31

Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients

Phase 2 Terminated

22 enrolled 7 charts

Breast Neoplasms

NCT00371345 2011-04-26

Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

Phase 2 Completed

92 enrolled 27 charts

Breast Neoplasms, Neoplasm Metastasis, Recurrence